Prostate cancer vaccines: the long road to clinical application

Cancer Immunology, Immunotherapy

Volumn 64, Issue 4, 2015, Pages 401-408

  Baxevanis, Constantin N ^a   Papamichail, Michael ^a   Perez, Sonia A ^a  

^a SAINT SAVVAS HOSPITAL   (Greece)

Author keywords

Biomarkers; Cancer vaccines; Cross presentation; Epitope spreading; Immunomodulation; Prostate cancer

Indexed keywords

BIOLOGICAL MARKER; CANCER VACCINE; EPITOPE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; HLA A24 ANTIGEN; HLA DR11 ANTIGEN; INTERLEUKIN 12; IPILIMUMAB; NIVOLUMAB; PROSTATE SPECIFIC ANTIGEN;

ACTIVE IMMUNIZATION; ANDROGEN DEPRIVATION THERAPY; ANTIGENICITY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CD8+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); CROSS PRESENTATION; DRUG POTENCY; EARLY DIAGNOSIS; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; IMMUNOMODULATION; IMMUNOREACTIVITY; IMMUNOSURVEILLANCE; MALE; MULTIMODALITY CANCER THERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE; PROSTATE CANCER; PROSTATE EPITHELIUM; REVIEW; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VOLUME; VACCINATION; IMMUNOLOGY; IMMUNOTHERAPY; PROSTATIC NEOPLASMS; TRANSLATIONAL RESEARCH; TRENDS;

CANCER VACCINES; HUMANS; IMMUNOTHERAPY; MALE; PROSTATIC NEOPLASMS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84925498921     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-015-1667-7     Document Type: Review

References (50)

1. Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331:1565–1570. doi:10.1126/science.1203486
2. Gulley JL, Madan RA, Schlom J (2011) Impact of tumour volume on the potential efficacy of therapeutic vaccines. Curr Oncol 18:e150–e157
3. Singh BH, Gulley JL (2014) Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances. Ther Adv Vaccines 2:137–148. doi:10.1177/2051013614539478
4. Bilusic M, Gulley JL (2012) Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines. Cancer Immunol Immunother 61:109–117. doi:10.1007/s00262-011-1141-0
5. Antonarakis ES, Drake CG (2012) Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy. Curr Opin Oncol 24:258–265. doi:10.1097/CCO.0b013e32835205a0
6. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G (2008) Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8:59–73. doi:10.1038/nri2216
7. Sheridan C (2014) Immune-checkpoint inhibitors march on, now in combinations. Nat Biotechnol 32:297–299. doi:10.1038/nbt0414-297
8. Jochems C, Tucker JA, Tsang KY, Madan RA, Dahut WL, Liewehr DJ, Steinberg SM, Gulley JL, Schlom J (2014) A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. Cancer Immunol Immunother 63:407–418. doi:10.1007/s00262-014-1524-0
9. Sercarz EE (2000) Driver clones and determinant spreading. J Autoimmun 14:275–277. doi:10.1006/jaut.2000.0380
10. Stein WD, Gulley JL, Schlom J et al (2011) Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res 17:907–917. doi:10.1158/1078-0432.CCR-10-1762
11. Perez SA, Anastasopoulou EA, Tzonis P, Gouttefangeas C, Kalbacher H, Papamichail M, Baxevanis CN (2013) AE37 peptide vaccination in prostate cancer: a 4-year immunological assessment updates on a phase I trial. Cancer Immunol Immunother 62:1599–1608. doi:10.1007/s00262-013-1461-3
12. Schlom J (2012) Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst 104:599–613. doi:10.1093/jnci/djs033
13. Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411–422. doi:10.1056/NEJMoa1001294
14. Hoos A, Eggermont AM, Janetzki S et al (2010) Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 102:1388–1397. doi:10.1093/jnci/djq310
15. Andersen BM, Ohlfest JR (2012) Increasing the efficacy of tumor cell vaccines by enhancing cross priming. Cancer Lett 325:155–164. doi:10.1016/j.canlet.2012.07.012
16. McDonnell AM, Prosser AC, van Bruggen I, Robinson BW, Currie AJ (2010) CD8alpha+ DC are not the sole subset cross-presenting cell-associated tumor antigens from a solid tumor. Eur J Immunol 40:1617–1627. doi:10.1002/eji.200940153
17. Peterson AC, Harlin H, Gajewski TF (2003) Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J Clin Oncol 21:2342–2348. doi:10.1200/JCO.2003.12.144
18. Vanderlugt CL, Miller SD (2002) Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2:85–95. doi:10.1038/nri724
19. Disis ML (2011) Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. Cancer Immunol Immunother 60:433–442. doi:10.1007/s00262-010-0960-8
20. Gulley JL, Arlen PM, Bastian A et al (2005) Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 11:3353–3362. doi:10.1158/1078-0432.CCR-04-2062
21. Lechleider RJ, Arlen PM, Tsang KY et al (2008) Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clin Cancer Res 14:5284–5291. doi:10.1158/1078-0432.CCR-07-5162
22. Madan RA, Mohebtash M, Arlen PM et al (2012) Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 13:501–508. doi:10.1016/S1470-2045(12)70006-2
23. Arlen PM, Gulley JL, Parker C et al (2006) A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 12:1260–1269. doi:10.1158/1078-0432.CCR-05-2059
24. Hodge JW, Garnett CT, Farsaci B, Palena C, Tsang KY, Ferrone S, Gameiro SR (2013) Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int J Cancer 133:624–636. doi:10.1002/ijc.28070
25. Kroemer G, Galluzzi L, Kepp O, Zitvogel L (2013) Immunogenic cell death in cancer therapy. Annu Rev Immunol 31:51–72. doi:10.1146/annurev-immunol-032712-100008
26. Chan OT, Yang LX (2000) The immunological effects of taxanes. Cancer Immunol Immunother 49:181–185
27. Mason K, Staab A, Hunter N, McBride W, Petersen S, Terry N, Milas L (2001) Enhancement of tumor radioresponse by docetaxel: involvement of immune system. Int J Oncol 18:599–606
28. Petrylak DP, Dawson NA, Gardner T et al (2010) Persistence of immunotherapy survival effects of sipuleucel-T and relationship to postrandomization docetaxel use in phase III studies. J Clin Oncol. 2010 ASCO Annual Meeting Abstracts. 28:4551
29. Ahmed MM, Hodge JW, Guha C, Bernhard EJ, Vikram B, Coleman CN (2013) Harnessing the potential of radiation-induced immune modulation for cancer therapy. Cancer Immunol Res 1:280–284. doi:10.1158/2326-6066.CIR-13-0141
30. Bernstein MB, Garnett CT, Zhang H, Velcich A, Wattenberg MM, Gameiro SR, Kalnicki S, Hodge JW, Guha C (2014) Radiation-induced modulation of costimulatory and coinhibitory T-cell signaling molecules on human prostate carcinoma cells promotes productive antitumor immune interactions. Cancer Biother Radiopharm 29:153–161. doi:10.1089/cbr.2013.1578
31. Postow MA, Callahan MK, Barker CA et al (2012) Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366:925–931. doi:10.1056/NEJMoa1112824
32. Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, Hodge JW (2004) External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res 64:4328–4337. doi:10.1158/0008-5472.CAN-04-0073
33. Heery CR, Madan RA, Bilusic M et al (2012) Interim analysis of a phase II randomized clinical trial of samrium-153 (Sm-153) with or without PSA-TRICOM vaccine in metastatic castration-resistant prostate cancer after docetaxel. J Clin Oncol. 2012 ASCO Annual Meeting Abstracts. 30:2526
34. Roden AC, Moser MT, Tri SD et al (2004) Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol 173:6098–6108
35. Sutherland JS, Goldberg GL, Hammett MV et al (2005) Activation of thymic regeneration in mice and humans following androgen blockade. J Immunol 175:2741–2753
36. Mercader M, Bodner BK, Moser MT et al (2001) T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci USA 98:14565–14570. doi:10.1073/pnas.251140998
37. Drake CG, Doody AD, Mihalyo MA et al (2005) Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 7:239–249. doi:10.1016/j.ccr.2005.01.027
38. Ardiani A, Farsaci B, Rogers CJ, Protter A, Guo Z, King TH, Apelian D, Hodge JW (2013) Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model. Clin Cancer Res 19:6205–6218. doi:10.1158/1078-0432.CCR-13-1026
39. Graff JN, Drake CG, Beer TM (2013) Complete biochemical (prostate-specific antigen) response to sipuleucel-T with enzalutamide in castration-resistant prostate cancer: a case report with implications for future research. Urology 81:381–383. doi:10.1016/j.urology.2012.10.044
40. Madan RA, Mohebtash M, Arlen PM, Vergati M, Steinberg SM, Tsang KY, Dahut WL, Schlom J, Gulley JL (2010) Overall survival (OS) analysis of a phase l trial of a vector-based vaccine (PSA-TRICOM) and ipilimumab (Ipi) in the treatment of metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2010 ASCO Annual Meeting Abstracts. 28:2550
41. van den Eertwegh AJM, de Gruijl T, Santegoets S et al (2012) Lymphoid and myeloid biomarkers for clinical outcome of combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells (GVAX) and ipilimumab in castration-resistant prostate cancer patients. J Clin Oncol. 2012 ASCO Annual Meeting Abstracts. 30:2562
42. Fridman WH, Pages F, Sautes-Fridman C, Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12:298–306. doi:10.1038/nrc3245
43. Whiteside TL (2013) Immune responses to cancer: Are they potential biomarkers of prognosis? Front Oncol 3:107. doi:10.3389/fonc.2013.00107
44. Weide B, Zelba H, Derhovanessian E et al (2012) Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. J Clin Oncol 30:1835–1841. doi:10.1200/JCO.2011.40.2271
45. Perez SA, Anastasopoulou EA, Papamichail M, Baxevanis CN (2014) AE37 peptide vaccination in prostate cancer: identification of biomarkers in the context of prognosis and prediction. Cancer Immunol Immunother 63:1141–1150. doi:10.1007/s00262-014-1582-3
46. De Petris L, Bergfeldt K, Hising C, Lundqvist A, Tholander B, Pisa P, van der Zanden HG, Masucci G (2004) Correlation between HLA-A2 gene frequency, latitude, ovarian and prostate cancer mortality rates. Med Oncol 21:49–52. doi:10.1385/MO:21:1:49
47. Tertipis N, Villabona L, Nordfors C, Nasman A, Ramqvist T, Vlastos A, Masucci G, Dalianis T (2014) HLA-A*02 in relation to outcome in human papillomavirus positive tonsillar and base of tongue cancer. Anticancer Res 34:2369–2375
48. Suzman DL, Antonarakis ES (2014) Castration-resistant prostate cancer: latest evidence and therapeutic implications. Ther Adv Med Oncol 6:167–179. doi:10.1177/1758834014529176
49. Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, Valone FH (2000) Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 18:3894–3903
50. Ojemuyiwa MA, Madan RA, Dahut WL (2014) Tyrosine kinase inhibitors in the treatment of prostate cancer: taking the next step in clinical development. Expert Opin Emerg Drugs 19:459–470. doi:10.1517/14728214.2014.969239